Sei Investments Co. lowered its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 17.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,807 shares of the medical research company’s stock after selling 33,221 shares during the quarter. Sei Investments Co. owned approximately 0.08% of Edwards Lifesciences Corporation worth $17,360,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. BNP Paribas Arbitrage SA raised its holdings in shares of Edwards Lifesciences Corporation by 43.6% during the third quarter. BNP Paribas Arbitrage SA now owns 137,404 shares of the medical research company’s stock valued at $15,020,000 after acquiring an additional 41,694 shares during the last quarter. FDx Advisors Inc. raised its holdings in shares of Edwards Lifesciences Corporation by 28.0% during the third quarter. FDx Advisors Inc. now owns 17,831 shares of the medical research company’s stock valued at $1,949,000 after acquiring an additional 3,902 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Edwards Lifesciences Corporation by 6.2% during the third quarter. Jennison Associates LLC now owns 1,033,376 shares of the medical research company’s stock valued at $112,958,000 after acquiring an additional 60,318 shares during the last quarter. Scout Investments Inc. raised its holdings in shares of Edwards Lifesciences Corporation by 0.9% during the third quarter. Scout Investments Inc. now owns 229,855 shares of the medical research company’s stock valued at $25,125,000 after acquiring an additional 2,127 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund increased its holdings in shares of Edwards Lifesciences Corporation by 7.1% in the third quarter. Oregon Public Employees Retirement Fund now owns 52,856 shares of the medical research company’s stock valued at $5,778,000 after purchasing an additional 3,493 shares during the last quarter. 82.17% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Corporation (NYSE:EW) traded down $0.09 during trading hours on Wednesday, reaching $105.15. The company had a trading volume of 994,900 shares, compared to its average volume of 1,644,831. The stock has a market capitalization of $22,250.00, a price-to-earnings ratio of 29.15, a PEG ratio of 1.89 and a beta of 0.46. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. During the same quarter in the prior year, the business earned $0.68 earnings per share. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. equities analysts anticipate that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current fiscal year.

In other Edwards Lifesciences Corporation news, Director Schack Wesley W. Von sold 1,000 shares of the firm’s stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $104.15, for a total value of $104,150.00. Following the sale, the director now directly owns 2,622 shares in the company, valued at $273,081.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $112.15, for a total value of $594,395.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 139,580 shares of company stock worth $15,143,994. 2.13% of the stock is owned by insiders.

EW has been the subject of several recent research reports. Zacks Investment Research raised Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target for the company in a report on Tuesday, July 18th. BidaskClub cut Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Jefferies Group LLC increased their price target on Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the company a “buy” rating in a report on Thursday, July 27th. Bank of America Corporation increased their price target on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, July 27th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $130.00 price target (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Seven research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $125.17.

COPYRIGHT VIOLATION WARNING: “Edwards Lifesciences Corporation (EW) Shares Sold by Sei Investments Co.” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/edwards-lifesciences-corporation-ew-shares-sold-by-sei-investments-co/1704776.html.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.